Denali Therapeutics Inc (NASDAQ: DNLI) on Tuesday, plunged -4.34% from the previous trading day, before settling in for the closing price of $14.76. Within the past 52 weeks, DNLI’s price has moved between $14.01 and $33.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 260.06%. The company achieved an average annual earnings per share of -12.77%. With a float of $125.71 million, this company’s outstanding shares have now reached $142.63 million.
The extent of productivity of a business whose workforce counts for 422 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Denali Therapeutics Inc (DNLI) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Denali Therapeutics Inc is 13.43%, while institutional ownership is 88.04%. The most recent insider transaction that took place on Jan 06 ’25, was worth 247,796. In this transaction Chief Medical Officer of this company sold 12,255 shares at a rate of $20.22, taking the stock ownership to the 178,580 shares. Before that another transaction happened on Jan 07 ’25, when Company’s Chief Medical Officer sold 2,907 for $20.81, making the entire transaction worth $60,495. This insider now owns 175,673 shares in total.
Denali Therapeutics Inc (DNLI) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -12.77% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.03% during the next five years compared to -4.46% drop over the previous five years of trading.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
Denali Therapeutics Inc (DNLI) is currently performing well based on its current performance indicators. A quick ratio of 8.46 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.58, a number that is poised to hit -0.70 in the next quarter and is forecasted to reach -2.58 in one year’s time.
Technical Analysis of Denali Therapeutics Inc (DNLI)
The latest stats from [Denali Therapeutics Inc, DNLI] show that its last 5-days average volume of 0.9 million was inferior to 1.09 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 12.87%. Additionally, its Average True Range was 1.03.
During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 0.57%, which indicates a significant decrease from 0.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.82% in the past 14 days, which was higher than the 67.01% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.40, while its 200-day Moving Average is $23.33. Now, the first resistance to watch is $14.65. This is followed by the second major resistance level at $15.18. The third major resistance level sits at $15.45. If the price goes on to break the first support level at $13.85, it is likely to go to the next support level at $13.57. Assuming the price breaks the second support level, the third support level stands at $13.04.
Denali Therapeutics Inc (NASDAQ: DNLI) Key Stats
Market capitalization of the company is 2.05 billion based on 145,215K outstanding shares. Right now, sales total 0 K and income totals -422,770 K. The company made 0 K in profit during its latest quarter, and -114,750 K in sales during its previous quarter.
